Literature DB >> 15917418

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.

C W Wong1, Y S Fan, T L Chan, A S W Chan, L C Ho, T K F Ma, S T Yuen, S Y Leung.   

Abstract

BACKGROUND: Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas. AIMS: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs.
METHODS: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing.
RESULTS: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas.
CONCLUSION: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917418      PMCID: PMC1770697          DOI: 10.1136/jcp.2004.022509

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  39 in total

1.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.

Authors:  Alexis Gorden; Iman Osman; Weiming Gai; Dan He; Weiqing Huang; Anne Davidson; Alan N Houghton; Klaus Busam; David Polsky
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

2.  Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.

Authors:  Rajiv Kumar; Sabrina Angelini; Kari Hemminki
Journal:  Oncogene       Date:  2003-12-18       Impact factor: 9.867

3.  BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.

Authors:  Pablo Uribe; Ignacio I Wistuba; Sergio González
Journal:  Am J Dermatopathol       Date:  2003-10       Impact factor: 1.533

4.  Determinants of BRAF mutations in primary melanomas.

Authors:  Janet L Maldonado; Jane Fridlyand; Hetal Patel; Ajay N Jain; Klaus Busam; Toshiro Kageshita; Tomomichi Ono; Donna G Albertson; Dan Pinkel; Boris C Bastian
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

5.  BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.

Authors:  Jianli Dong; Robert G Phelps; Rui Qiao; Shen Yao; Outhiriaradjou Benard; Zeev Ronai; Stuart A Aaronson
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

6.  Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.

Authors:  Julia Reifenberger; Christiane B Knobbe; Astrid A Sterzinger; Britta Blaschke; Klaus W Schulte; Thomas Ruzicka; Guido Reifenberger
Journal:  Int J Cancer       Date:  2004-04-10       Impact factor: 7.396

7.  Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Authors:  Amir S Yazdi; Gabriele Palmedo; Michael J Flaig; Ursula Puchta; Andrea Reckwerth; Arno Rütten; Thomas Mentzel; Heino Hügel; Markus Hantschke; Monika-Hildegard Schmid-Wendtner; Heinz Kutzner; Christian A Sander
Journal:  J Invest Dermatol       Date:  2003-11       Impact factor: 8.551

8.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Authors:  Katarina Omholt; Anton Platz; Lena Kanter; Ulrik Ringborg; Johan Hansson
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

9.  Absence of BRAF and NRAS mutations in uveal melanoma.

Authors:  Frank Cruz; Brian P Rubin; David Wilson; Ajia Town; Arin Schroeder; Andrea Haley; Troy Bainbridge; Michael C Heinrich; Christopher L Corless
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Lack of BRAF mutations in uveal melanoma.

Authors:  Donata Rimoldi; Suzanne Salvi; Danielle Liénard; Ferdy J Lejeune; Daniel Speiser; Leonidas Zografos; Jean-Charles Cerottini
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  37 in total

1.  Molecular alterations in malignant blue nevi and related blue lesions.

Authors:  Ismail Yilmaz; Mehmet Gamsizkan; Sule Ozturk Sari; Banu Yaman; Cuyan Demirkesen; Aylin Heper; Aylin Orgen Calli; Gizem Narli; Zafer Kucukodaci; Ufuk Berber; Dilaver Demirel; Taner Akalin; Murat Demiriz; Nesimi Buyukbabani
Journal:  Virchows Arch       Date:  2015-09-24       Impact factor: 4.064

2.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

3.  Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Piotr Waloszczyk; Marek Masiuk; Jaroslaw Wejman; Justyna Szumilo; Markku Miettinen
Journal:  Mod Pathol       Date:  2019-02-13       Impact factor: 7.842

Review 4.  Rare presentations of primary melanoma and special populations: a systematic review.

Authors:  Lisa A Kottschade; Travis E Grotz; Roxana S Dronca; Diva R Salomao; Jose S Pulido; Nabil Wasif; James W Jakub; Sanjay P Bagaria; Riten Kumar; Judith S Kaur; Shane Y Morita; Steven L Moran; Jesse T Nguyen; Emily C Nguyen; Jennifer L Hand; Lori A Erickson; Jerry D Brewer; Christian L Baum; Robert C Miller; David L Swanson; Val Lowe; Svetomir N Markovic
Journal:  Am J Clin Oncol       Date:  2014-12       Impact factor: 2.339

5.  Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.

Authors:  Stephan W Jahn; Karl Kashofer; Iris Halbwedl; Gerlinde Winter; Laila El-Shabrawi-Caelen; Thomas Mentzel; Gerald Hoefler; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2015-03-13       Impact factor: 7.842

6.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

7.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

8.  There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis.

Authors:  Rolf K Swoboda; Meenhard Herlyn
Journal:  Exp Dermatol       Date:  2013-03-12       Impact factor: 3.960

9.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

10.  Basonuclin-2 requirements for zebrafish adult pigment pattern development and female fertility.

Authors:  Michael R Lang; Larissa B Patterson; Tiffany N Gordon; Stephen L Johnson; David M Parichy
Journal:  PLoS Genet       Date:  2009-11-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.